Norisoboldine, an alkaloid from Radix linderae, inhibits NFAT activation and attenuates 2,4-dinitrofluorobenzene-induced dermatitis in mice

References

• Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5:472–484.
   PubMed Web of Science ®Google Scholar
• Shaw JP, Utz PJ, Durand DB, et al. Identification of a putative regulator of early T cell activation genes. Science 1988;241:202–205.
   PubMed Web of Science ®Google Scholar
• Masuda ES, Imamura R, Amasaki Y, et al. Signalling into the T-cell nucleus: NFAT regulation. Cell Signal 1998;10:599–611.
   PubMed Web of Science ®Google Scholar
• Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009;19:277–284.
   PubMed Web of Science ®Google Scholar
• Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2007;19:238–245.
   PubMed Web of Science ®Google Scholar
• Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007;13:245–253.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606–619.
   PubMed Web of Science ®Google Scholar
• Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015;7:CD009864.
   PubMedGoogle Scholar
• Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2001;2:1167–1175.
   PubMedGoogle Scholar
• Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013;15:303–310.
   PubMed Web of Science ®Google Scholar
• Pleasant L, Skinner S, Pulliam J, et al. Burkitt lymphoma in a child with atopic dermatitis and a 7-year history of regular topical tacrolimus use. Cutis 2012;89:117–120.
   PubMed Web of Science ®Google Scholar
• Luo Y, Liu M, Xia Y, et al. Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice. Phytomedicine 2010;17:726–731.
   PubMed Web of Science ®Google Scholar
• Wei ZF, Jiao XL, Wang T, et al. Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression. Acta Pharmacol Sin 2013;34:403–413.
   PubMed Web of Science ®Google Scholar
• Tong B, Dou Y, Wang T, et al. Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues. Toxicol Appl Pharmacol 2015;282:90–99.
   PubMed Web of Science ®Google Scholar
• Wei ZF, Tong B, Xia YF, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-kappaB/c-Fos/NFATc1 pathways. PLoS One 2013;8:e59171.
   PubMed Web of Science ®Google Scholar
• Wei ZF, Lv Q, Xia Y, et al. Norisoboldine, an anti-arthritis alkaloid isolated from Radix linderae, attenuates osteoclast differentiation and inflammatory bone erosion in an aryl hydrocarbon receptor-dependent manner. Int J Biol Sci 2015;11:1113–1126.
   PubMed Web of Science ®Google Scholar
• Luo Y, Liu M, Dai Y, et al. Norisoboldine inhibits the production of pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 cells by down-regulating the activation of MAPKs but not NF-κB. Inflammation 2010;33:389–397.
   PubMed Web of Science ®Google Scholar
• Wei Z, Wang F, Song J, et al. Norisoboldine inhibits the production of interleukin-6 in fibroblast-like synoviocytes from adjuvant arthritis rats through PKC/MAPK/NF-κB-p65/CREB pathways. J Cell Biochem 2012;113:2785–2795.
   PubMed Web of Science ®Google Scholar
• Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807–815.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou CL, Lei H, et al. Kaempferol: a new immunosuppressant of calcineurin. IUBMB Life 2008;60:549–554.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou CL, Lei H, Wei Q. Inhibition of calcineurin by quercetin in vitro and in Jurkat cells. J Biochem 2010;147:185–190.
   PubMed Web of Science ®Google Scholar
• Gorbachev AV, Fairchild RL. Induction and regulation of T-cell priming for contact hypersensitivity. Crit Rev Immunol 2001;21:451–472.
   PubMed Web of Science ®Google Scholar
• Saint-Mezard P, Berard F, Dubois B, et al. The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis. Eur J Dermatol 2004;14:131–138.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Takeuchi H, Sakuma S, et al. Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. Skin Pharmacol Physiol 2009;22:240–247.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim HG, Jin SW, et al. Topical application of Pleurotus eryngii extracts inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by the regulation of Th1/Th2 balance. Food Chem Toxicol 2013;53:38–45.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009;231:241–256.
   PubMed Web of Science ®Google Scholar
• Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000;97:1196–1201.
   PubMed Web of Science ®Google Scholar
• Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004;322:1178–1191.
   PubMed Web of Science ®Google Scholar
• Viola JP, Carvalho LD, Fonseca BP, Teixeira LK. NFAT transcription factors: from cell cycle to tumor development. Braz J Med Biol Res 2005;38:335–344.
   PubMed Web of Science ®Google Scholar
• Lu H, Huan C. Transcription factor NFAT, its role in cancer development, and as a potential target for chemoprevention. Curr Cancer Drug Targets 2007;7:343–353.
   PubMed Web of Science ®Google Scholar